OncoSec Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>OM</div>
ONCS -- USA Stock  

USD 7.23  0.14  1.97%

OncoSec Medical Price to Book Value is relatively stable at the moment as compared to the past year. OncoSec Medical reported last year Price to Book Value of 6.97. As of 12/16/2020, Tangible Assets Book Value per Share is likely to grow to 1.86, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (43.2 M). OncoSec Medical Inco is scheduled to announce its earnings today. While some generation-Y investors are indifferent towards healthcare space, it makes sense to sum up OncoSec Medical Incorporated using its fundamentals . We will evaluate if OncoSec Medical shares are reasonably priced going into January. Will retail investors continue to hold, or should we expect a sell-off?
Published over a month ago
View all stories for OncoSec Medical | View All Stories
Does OncoSec Medical (NASDAQ:ONCS) have invariable basic indicators based on the latest spike?
OncoSec Medical is UNDERVALUED at 6.40 per share with modest projections ahead. OncoSec Medical appears to be relatively risky, given 1 month investment horizon. OncoSec Medical Inco maintains Sharpe Ratio (i.e. Efficiency) of 0.0733, which implies the firm had 0.0733% of return per unit of risk over the last month. Our standpoint towards forecasting the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for OncoSec Medical Inco, which you can use to evaluate future volatility of the company. Please employ OncoSec Medical Inco Semi Deviation of 3.86, coefficient of variation of 678.96, and Risk Adjusted Performance of 0.2115 to confirm if our risk estimates are consistent with your expectations.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include OncoSec Medical income statement, its balance sheet, and the statement of cash flows. Potential OncoSec Medical investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although OncoSec Medical investors may use each financial statement separately, they are all related. The changes in OncoSec Medical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on OncoSec Medical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of OncoSec Medical fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of OncoSec Medical performance into the future periods or doing a reasonable stock valuation. The intrinsic value of OncoSec Medical shares is the value that is considered the true value of the share. If the intrinsic value OncoSec is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares OncoSec Medical. Please read more on our fundamental analysis page.

Are OncoSec Medical Earnings Expected to grow?

The future earnings power of OncoSec Medical involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of OncoSec Medical factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. OncoSec Medical stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of OncoSec expected earnings.

How OncoSec utilizes its cash?

To perform a cash flow analysis of OncoSec Medical, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash OncoSec Medical is receiving and how much cash it distributes out in a given period. The OncoSec Medical cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Another Deeper Perspective

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of OncoSec Medical is not uncomon. There are few distinct groups of OncoSec Medical stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of OncoSec is distributed among investors.

Ownership Allocation

OncoSec Medical Inco has a total of 27.96 Million outstanding shares. OncoSec Medical has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors
34.31%
Insiders
57.75%
Institutions
7.94%
Retail Investors34.31
Insiders57.75
Institutions7.94

Asset Utilization

One of the ways to look at asset utilization of OncoSec is to check how much profit was generated for every dollar of assets it reports. OncoSec Medical holds a negative application of assets of -101.91 pct., losing $1.02 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of OncoSec Medical Incorporated shows how discouraging it operates for each dollar spent on its assets.

Current Assets
22.9 M
Assets Non Current
7.6 M
Current Assets22.92 Million73.96
Assets Non Current7.64 Million24.65
Goodwill429,2301.38

Our perspective of the latest OncoSec Medical spike

Latest semi deviation is at 3.86. OncoSec Medical Incorporated shows above-average downside volatility for the selected time horizon. We advise investors to inspect OncoSec Medical Incorporated further and ensure that all market timing and asset allocation strategies are consistent with the estimation of OncoSec Medical future alpha.

The Bottom Line

While other companies within the biotechnology industry are still a little expensive, even after the recent corrections, OncoSec Medical may offer a potential longer-term growth to retail investors. On the whole, as of the 16th of December 2020, our concluding 30 days advice on the enterprise is Hold. We believe OncoSec Medical is currently undervalued with below average probability of bankruptcy for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of OncoSec Medical Incorporated. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com